Published in Obesity and Diabetes Week, January 25th, 2010
"We are very excited by the discovery of ACE-435, which represents an entirely different approach to treating metabolic disease," said Jas Seehra, Ph.D., Chief Scientific Officer and Co-Founder of Acceleron Pharma. "In preclinical studies, ACE-435 affects brown fat, resulting in reduced white fat mass...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week